Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Jules Bordet Institute19 enrolled

Overview

First line treatment for advanced ovarian carcinoma hyperthermic intraperitoneal chemotherapy (HIPEC) after optimal debulking.

Addition of HIPEC to the standard first line treatment of ovarian carcinoma.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Ovarian Carcinoma Fallopian Tube Carcinoma Primary Peritoneal Carcinoma

Interventions

HIPECPROCEDURE

HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * stage III or only pleural stage IV ovarian carcinoma first line treatment Exclusion Criteria: * incomplete surgery poor performance status bad general condition

Locations (2)

Hopital de la Citadelle

Liège, Liège, Belgium

Institut Jules Bordet

Brussels, Belgium

Outcomes

Primary Outcomes

mortality rate

We will record the mortality rate of our interventions: 3 cycles of pre-operative chemotherapy, surgery and HIPEC, 3 cycles of post-operative chemotherapy.

Time frame: 24 weeks

Secondary Outcomes

progression free survival

Time frame: 3 years

Overall survival

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.